Positive Meta-analysis Result

Deltex Medical Group PLC
26 September 2006


                            Deltex Medical Group plc

Presentation of independent systematic review and meta-analysis of clinical data
        supporting the use of CardioQTM to reduce length of hospital stay


26 September 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today highlights the
presentation of the first systematic review and meta-analysis of the published
clinical data involving use of peri-operative oesophageal Doppler-guided fluid
delivery, a technique which enables doctors to identify and deal with reductions
in circulating blood volume that arise as a consequence of surgery and are
associated with potentially serious complications.

Dr Mark Hamilton, on behalf of co-authors from the Centre for Anaesthesia,
University College London and St George's Hospital, London, today presented the
results of their review at the European Society of Intensive Care Medicine
(ESICM) meeting in Barcelona. The review's primary conclusion was that giving
fluid, guided by oesophageal Doppler, significantly reduced hospital length of
stay for surgical patients compared to traditional fluid management.

Healthcare providers around the world employ meta-analyses to support decisions
about funding and reimbursement of new medical technologies. Examples of
organisations that undertake such analyses are the National Institute for Health
and Clinical Excellence (NICE) in the UK and the Agency for Health Research and
Quality (AHRQ) in the USA.

Dr Hamilton commented:

'The use of targeted oesophageal Doppler monitoring in the peri-operative period
significantly reduces hospital length of stay for surgical patients. There are
obvious economic and healthcare benefits to greater use of this simple
technology.'

Deltex Medical's chief executive, Andy Hill, commented:

'This is the first systematic review of the impact of oesophageal Doppler-guided
therapy based on the overwhelming body of clinical data published to date. The
positive conclusions reported by Dr Hamilton will only be further strengthened
by the addition of the recently published trial from the Freeman hospital in
Newcastle that was unavailable for inclusion at the time the review was
submitted for presentation by Dr Hamilton.

'The CardioQ oesophageal Doppler haemodynamic monitor has been proven in
multiple randomised clinical trials to improve outcomes and reduce length of
stay following surgery. I believe that this meta-analysis clearly demonstrates
the urgent need to implement the CardioQ as a standard of care for patients
undergoing major surgery.'


For further information, please contact:-

Deltex Medical Group plc                     01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director


Gavin Anderson & Company                     020 7554 1400
Deborah Walter
Marie Cairney
Jodie Reilly


Charles Stanley Securities                   020 7149 6457
Philip Davies


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the 
CardioQ which have repeatedly:-


   •    Validated the results of the Monitor against known standards for
        measuring cardiac output, demonstrating that the technology works

   •    Proved that the CardioQ works in a wide range of surgical procedures

   •    Demonstrated that the Company's technology provides significant health
        and economic benefits by helping to reduce post-operative complications 
        and length of hospital stays by an average of 30 to 40 per cent for a 
        wide range of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange